Literature DB >> 29237794

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Ryan R Walsh1, Florian Krismer2, Wendy R Galpern2, Gregor K Wenning2, Phillip A Low2, Glenda Halliday2, Walter J Koroshetz2, Janice Holton2, Niall P Quinn2, Olivier Rascol2, Leslie M Shaw2, David Eidelberg2, Pam Bower2, Jeffrey L Cummings2, Victor Abler2, Judy Biedenharn2, Gal Bitan2, David J Brooks2, Patrik Brundin2, Hubert Fernandez2, Philip Fortier2, Roy Freeman2, Thomas Gasser2, Art Hewitt2, Günter U Höglinger2, Matt J Huentelman2, Poul H Jensen2, Andreas Jeromin2, Un Jung Kang2, Horacio Kaufmann2, Lawrence Kellerman2, Vikram Khurana2, Thomas Klockgether2, Woojin Scott Kim2, Carol Langer2, Peter LeWitt2, Eliezer Masliah2, Wassilios Meissner2, Ronald Melki2, Susanne Ostrowitzki2, Steven Piantadosi2, Werner Poewe2, David Robertson2, Cyndi Roemer2, Dale Schenk2, Michael Schlossmacher2, Jeremy D Schmahmann2, Klaus Seppi2, Lily Shih2, Andrew Siderowf2, Glenn T Stebbins2, Nadia Stefanova2, Shoji Tsuji2, Sharon Sutton2, Jing Zhang2.   

Abstract

Multiple system atrophy (MSA) is a rare neurodegenerative disorder with substantial knowledge gaps despite recent gains in basic and clinical research. In order to make further advances, concerted international collaboration is vital. In 2014, an international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to identify critical research areas where consensus and progress was needed to improve understanding, diagnosis, and treatment of the disease. Eight topic areas were defined: pathogenesis, preclinical modeling, target identification, endophenotyping, clinical measures, imaging biomarkers, nonimaging biomarkers, treatments/trial designs, and patient advocacy. For each topic area, an expert served as a working group chair and each working group developed priority-ranked research recommendations with associated timelines and pathways to reach the intended goals. In this report, each groups' recommendations are provided.
Copyright © 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 29237794      PMCID: PMC5772155          DOI: 10.1212/WNL.0000000000004798

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Survival of patients with pathologically proven multiple system atrophy: a meta-analysis.

Authors:  Y Ben-Shlomo; G K Wenning; F Tison; N P Quinn
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

2.  Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases.

Authors:  A Chiò; C Magnani; D Schiffer
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

3.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

Authors:  G K Wenning; Y Ben Shlomo; M Magalhães; S E Daniel; N P Quinn
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

4.  Multiple system atrophy: the case for an international collaborative effort.

Authors:  Lucy Norcliffe-Kaufmann; Jose-Alberto Palma; Florian Krismer
Journal:  Clin Auton Res       Date:  2015-04-11       Impact factor: 4.435

Review 5.  Recommendations of the Alzheimer's disease-related dementias conference.

Authors:  Thomas J Montine; Walter J Koroshetz; Debra Babcock; Dennis W Dickson; Wendy R Galpern; M Maria Glymour; Steven M Greenberg; Michael L Hutton; David S Knopman; Andrey N Kuzmichev; Jennifer J Manly; Karen S Marder; Bruce L Miller; Creighton H Phelps; William W Seeley; Beth-Anne Sieber; Nina B Silverberg; Margaret Sutherland; Christine L Torborg; Salina P Waddy; Berislav V Zlokovic; Roderick A Corriveau
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

6.  Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz
Journal:  J Neurol       Date:  2012-08-05       Impact factor: 4.849

7.  Survival in multiple system atrophy.

Authors:  Anette Schrag; Gregor K Wenning; Niall Quinn; Yoav Ben-Shlomo
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

Review 8.  The neuropathology, pathophysiology and genetics of multiple system atrophy.

Authors:  Z Ahmed; Y T Asi; A Sailer; A J Lees; H Houlden; T Revesz; J L Holton
Journal:  Neuropathol Appl Neurobiol       Date:  2012-02       Impact factor: 8.090

Review 9.  Animal models of multiple system atrophy.

Authors:  Nadia Stefanova; Gregor K Wenning
Journal:  Clin Auton Res       Date:  2015-01-14       Impact factor: 4.435

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more
  7 in total

1.  Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.

Authors:  C Alves Do Rego; I J Namer; C Marcel; F Lefebvre; O Lagha-Boukbiza; M Renaud; C Tranchant; M Anheim
Journal:  J Neurol       Date:  2018-06-28       Impact factor: 4.849

Review 2.  Can infections trigger alpha-synucleinopathies?

Authors:  Christopher T Tulisiak; Gabriela Mercado; Wouter Peelaerts; Lena Brundin; Patrik Brundin
Journal:  Prog Mol Biol Transl Sci       Date:  2019-07-03       Impact factor: 3.622

Review 3.  Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.

Authors:  Matthew J Betts; Evgeniya Kirilina; Maria C G Otaduy; Dimo Ivanov; Julio Acosta-Cabronero; Martina F Callaghan; Christian Lambert; Arturo Cardenas-Blanco; Kerrin Pine; Luca Passamonti; Clare Loane; Max C Keuken; Paula Trujillo; Falk Lüsebrink; Hendrik Mattern; Kathy Y Liu; Nikos Priovoulos; Klaus Fliessbach; Martin J Dahl; Anne Maaß; Christopher F Madelung; David Meder; Alexander J Ehrenberg; Oliver Speck; Nikolaus Weiskopf; Raymond Dolan; Ben Inglis; Duygu Tosun; Markus Morawski; Fabio A Zucca; Hartwig R Siebner; Mara Mather; Kamil Uludag; Helmut Heinsen; Benedikt A Poser; Robert Howard; Luigi Zecca; James B Rowe; Lea T Grinberg; Heidi I L Jacobs; Emrah Düzel; Dorothea Hämmerer
Journal:  Brain       Date:  2019-09-01       Impact factor: 13.501

4.  A case of multiple system atrophy.

Authors:  Jing Guo; Fuying Liu; Tingting Liu; Xin Zhang; Yong Luo
Journal:  J Int Med Res       Date:  2019-09-25       Impact factor: 1.671

5.  α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy.

Authors:  Suman Dutta; Simon Hornung; Adira Kruayatidee; Katherine N Maina; Irish Del Rosario; Kimberly C Paul; Darice Y Wong; Aline Duarte Folle; Daniela Markovic; Jose-Alberto Palma; Geidy E Serrano; Charles H Adler; Susan L Perlman; Wayne W Poon; Un Jung Kang; Roy N Alcalay; Miriam Sklerov; Karen H Gylys; Horacio Kaufmann; Brent L Fogel; Jeff M Bronstein; Beate Ritz; Gal Bitan
Journal:  Acta Neuropathol       Date:  2021-05-15       Impact factor: 15.887

6.  Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping.

Authors:  Alain Ndayisaba; Ariana T Pitaro; Andrew S Willett; Kristie A Jones; Claudio Melo de Gusmao; Abby L Olsen; Jisoo Kim; Eero Rissanen; Jared K Woods; Sharan R Srinivasan; Anna Nagy; Amanda Nagy; Merlyne Mesidor; Steven Cicero; Viharkumar Patel; Derek H Oakley; Idil Tuncali; Katherine Taglieri-Noble; Emily C Clark; Jordan Paulson; Richard C Krolewski; Gary P Ho; Albert Y Hung; Anne-Marie Wills; Michael T Hayes; Jason P Macmore; Luigi Warren; Pamela G Bower; Carol B Langer; Lawrence R Kellerman; Christopher W Humphreys; Bonnie I Glanz; Elodi J Dielubanza; Matthew P Frosch; Roy L Freeman; Christopher H Gibbons; Nadia Stefanova; Tanuja Chitnis; Howard L Weiner; Clemens R Scherzer; Sonja W Scholz; Dana Vuzman; Laura M Cox; Gregor Wenning; Jeremy D Schmahmann; Peter Novak; Geoffrey S Young; Mel B Feany; Tarun Singhal; Vikram Khurana
Journal:  Cerebellum       Date:  2022-10-03       Impact factor: 3.648

7.  The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question-are polyphenols a viable therapeutic option against proteinopathies?

Authors:  Gal Bitan
Journal:  Ann Transl Med       Date:  2020-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.